SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in the U.S. midterms and prospects of a sweep are driving QQQ discussion, with traders connecting the selloff to fears of tighter AI and data-center rules and a rotation out of tech. Views are split between further pressure on AI-linked stocks and a possible relief bounce, with some arguing the reaction is overdone or that gridlock could limit policy changes.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

A projected Democratic sweep in the midterms dominates discussion, with traders linking the anticipated loss of Republican control to pressure on Trump Media and many voicing bearish views on the stock. The community is largely celebrating the political setback, though some posts dispute the projected results or expect Republicans to retain control.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

The midterm election results are driving debate over perceived political risk to SpaceX, with traders fearing increased scrutiny of Musk, government contracts, and data-center projects; these consequences remain speculative. The community is split between bearish calls for further losses and buyers treating the selloff as an opportunity, with some noting a rebound.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

A heavily political debate over an expected Democratic midterm sweep dominates, with traders linking Teslas selloff to possible scrutiny of Elon Musk, reduced political support, and greater uncertainty around a potential SpaceX merger. Most commentary is bearish, while some traders argue Democrats could restore EV incentives or see the drop as a buying opportunity; the election-related claims remain speculative in the discussion.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Midterm-election uncertainty is driving debate over whether Democratic gains could bring tighter AI and data-center rules, pressuring Nvidia and the broader AI trade; others argue gridlock would limit policy changes and infrastructure demand remains strong. Traders also point to AMDs strong results as evidence of resilient AI-chip demand, alongside a rebound in semiconductor stocks.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Midterm-election fears over potential data-center restrictions dominated discussion, with traders linking the volatility in Micron and other AI-linked stocks to uncertainty about the results. Bulls argued that AI infrastructure and memory demand remain intact, while AMDs strong results helped fuel hopes of a semiconductor rebound; others remained wary of the sharp swings and memory-cycle risks.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs stronger-than-expected quarterly results and upbeat outlook, driven by AI and data-center demand, are drawing attention and fueling a bullish reaction. Traders are debating whether that growth can outweigh concerns about valuation, cash flow, and possible data-center restrictions tied to election outcomes.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXLs volatility is centered on election-related fears that a Democratic sweep could bring data-center restrictions and slow AI chip demand; others argue the concern is overblown and point to strong AMD and SMCI earnings as support for a semiconductor rebound.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is rebounding as traders point to Apples warning that memory costs are expected to keep rising, which they see as support for memory makers pricing amid AI and data-center demand. The bounce follows a sharp selloff, and skepticism persists over whether the memory upcycle can last and whether data-center spending will hold up.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros much-better-than-expected quarterly results and higher fiscal-year outlook, driven by AI-server demand, dominate discussion. Many traders see the results as bullish but are frustrated that the shares gave back part of their post-earnings gains; others cite thin margins, cash-flow and customer-concentration risks, lingering trust concerns, and election-related market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

Equity

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.read more...

Earnings Scheduled For September 21, 2026

Companies Reporting Before The Bell
 Ennis (NYSE:EBF) is expected to report earnings for its second quarter.
Companies Reporting After The Bell
 Abivax (NASDAQ:ABVX) is projected to report quarterly loss at $1.08 perread more...

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

Stocks in focus: Abivax, Marygold and Neuphoria report losses; Accenture partners with Anthropic, while Lobo Technologies posts H1 growth.read more...

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abivax will report H1 earnings Sept. 21; analysts expect a $1.08 loss/share and $1.86M revenue.read more...

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds 

Abivax said underwriters have fully exercised their option to purchase an additional 960,000 American depositary shares as part of their $920 million offering.

Abivax Prices $800M Offering Of ADS – Here’s A Look At Some Key Figures

The size of the offering was increased to $800 million from the previously announced offering of $600 million in ADSs.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Bearish Sentiment

<ul class="summary-bullets"><li>TRAX plans to release top-line data from the first ANB033 celiac-disease study cohort on Monday.</li><li>CYTK will present additional Aficamten analyses at HFSA, while EPRX presents previously disclosed EP-104GI data at ACG.</li><li>ARWR and VSTM have clinical updates scheduled for Wednesday on Alzheimer’s research and the cancer drug VS-7375.</li></ul><p>Biotech investors face a packed week, with First Tracks set to report early data on a celiac-disease drug, Verastem preparing an update on a cancer treatment, and the FDA approaching decisions on two eye therapies.</p><p>The&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> gained 2.8% last week, outperforming&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a>, up 1.2%, and&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>, up 0.2%. The&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> rose 0.6%, trailing SPY but beating QQQ, while the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 0.4%.</p><p><img src="https://news.stocktwits-cdn.com/healthcare_d7c3a475bc.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.12</td><td>TRAX</td><td>First Tracks plans to report Cohort 1 top-line data for ANB033 in celiac disease; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.12</td><td>CYTK / HFSA</td><td>Two late-breaking analyses of Aficamten in nonobstructive hypertrophic cardiomyopathy at the HFSA meeting</td></tr><tr><td>Oct.12</td><td>EPRX / ACG</td><td>Poster on EP-104GI and dysphagia improvements through 52 weeks in the RESOLVE study</td></tr><tr><td>Oct.13</td><td>JNJ</td><td>Third-quarter results; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.14</td><td>ARWR</td><td>Webinar with interim clinical data from the ARO-MAPT study in Alzheimer’s disease and other tauopathies</td></tr><tr><td>Oct.14</td><td>VSTM</td><td>Investor event with initial efficacy and updated safety data for VS-7375</td></tr><tr><td>Oct.14-Oct.17</td><td>PHAR / ESID</td><td>Late-breaking presentation of Phase 2 Leniolisib data in primary immunodeficiencies with immune dysregulation</td></tr><tr><td>Oct.15</td><td>RHHBY</td><td>FDA target action date for Roche’s Enspryng in thyroid eye disease</td></tr><tr><td>Oct.17</td><td>VTRS / IRD</td><td>FDA target action date for phentolamine ophthalmic solution 0.75% in presbyopia</td></tr><tr><td>Oct.17-Oct.20</td><td>UEG Week</td><td>Gastroenterology conference in Barcelona, with presentations from EPRX, ABVX, Agomab and PALI</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Monday: TRAX, CYTK and EPRX</strong></h2><p>First Tracks Biotherapeutics plans to report top-line data on Monday from Cohort 1 of its Phase 1b study of ANB033, a drug that blocks the immune target CD122. The gluten-challenge study is testing whether the drug can protect the intestinal lining from damage in people with celiac disease.&nbsp;</p><p>Cytokinetics (CYTK) will present two late-breaking analyses of Aficamten on Monday at the Heart Failure Society of America’s meeting in Phoenix. The ACACIA-HCM analyses examine the drug’s overall effectiveness and impact on exercise performance in nonobstructive hypertrophic cardiomyopathy, where a thickened heart muscle does not block blood flow. The company plans to submit a supplemental new drug application in the fourth quarter.&nbsp;</p><p>Eupraxia Pharmaceuticals (EPRX) will present a poster on Monday at the American College of Gastroenterology meeting on EP-104GI in eosinophilic esophagitis, an inflammatory condition of the esophagus. It will examine improvements in difficulty swallowing that lasted up to 52 weeks in the Phase 1b/2 Resolve study. Eupraxia reported the 52-week results from its highest-dose group late last month.&nbsp;</p><h2 class="st-heading-2"><strong>Midweek: JNJ, ARWR And VSTM</strong></h2><p>Johnson &amp; Johnson (JNJ) will report its third-quarter results on Tuesday. According to Koyfin, analysts expect revenue of $25.38 billion, up 0.3%. They forecast earnings before interest, taxes, depreciation and amortization (EBITDA) at $8.24 billion, down 8%, and earnings before interest and taxes (EBIT) at $7.42 billion, down 10%. GAAP earnings per share (EPS) are projected at $2.07, down 9%.</p><p>On Wednesday, Arrowhead Pharmaceuticals (ARWR) will share interim results from an early-stage study of ARO-MAPT, its treatment for Alzheimer’s disease and other disorders linked to abnormal tau protein. A webinar on the same day will also include an update on the company’s central nervous system pipeline.</p><p>Verastem Oncology (VSTM) will host an investor event on Wednesday to present initial efficacy results and updated safety data for VS-7375. The oral drug targets KRAS G12D, a cancer-driving mutation, and is being studied in pancreatic, lung and colorectal cancers as part of the Target-D program.</p><h2 class="st-heading-2"><strong>FDA Target Dates Loom For 2 Eye Treatments</strong></h2><p>Roche (RHHBY) is awaiting an FDA decision by Thursday on its application to use Enspryng (Satralizumab) to treat thyroid eye disease. The application received Priority Review. If approved, Roche says Enspryng could become the first at-home, under-the-skin treatment for the condition. The Phase 3 SatraGO results were presented last year.</p><p>Viatris (VTRS) and Opus Genetics (IRD) face an Oct.17 FDA target date for phentolamine eye drops, also known as MR-141, as a treatment for presbyopia — the age-related difficulty focusing on nearby objects. The FDA accepted the application seeking approval for this new use.</p><h2 class="st-heading-2"><strong>GI Conferences Bring More Data Presentations</strong></h2><p>Pharming (PHAR) will present previously announced Phase 2 results for Leniolisib at the European Society for Immunodeficiencies meeting, running Oct.14-Oct.17 in the Netherlands. The study involved patients with rare, genetically defined immune disorders. Pharming released the top-line findings last month.&nbsp;</p><p>Meanwhile, the United European Gastroenterology Week runs from Oct.17-Oct.20 in Barcelona. Abivax (ABVX) will present seven Obefazimod abstracts, including results from a Phase 3 maintenance study and patient subgroup analyses, longer-term Phase 2 findings and a preclinical study.</p><p>Agomab will present long-term data from an extension of its STENOVA Phase 2a study, in which patients continued Ontunisertib treatment for up to 60 weeks. The study focuses on fibrostenosing Crohn’s disease, which can cause narrowing of the bowel. Palisade Bio (PALI) will make four presentations on PALI-2108, including Phase 1b findings on early clinical improvements and evidence that the drug affects PDE4, a protein involved in inflammation. Three additional posters will cover gut-targeted delivery, safety and potential biomarkers that could help predict treatment response.</p><p>Separately, Filana Therapeutics (FLNA) said it will attend the Maxim Growth Summit, running Oct.12-Oct.14, for one-on-one meetings.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-big-pharma-buyout-booth-ash/cZx4tMpRBF7">SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&amp;A Negotiation Lounge' Booth At ASH&nbsp;</a></p>

Current Price	$88.71
Prev Close	$84.91
Open	$85.37
Dividend Yield	0.00%
50-Day Moving Average	$98.99
Beta	1.11
Avg. Volume	1.07M
PE Ratio	-14.53

52-Week High	$148.83
52-Week Low	$69.81
Market Capitalization	$7.77B
EPS (Annual)	-$5.46
Price to Book	16.91
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABVX Fundamentals